中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2013年
18期
38-41
,共4页
王小芳%张金盈%李凌%赵晓燕%姚海木
王小芳%張金盈%李凌%趙曉燕%姚海木
왕소방%장금영%리릉%조효연%요해목
依折麦布%瑞舒伐他汀%冠心病临界病变%超敏C-反应蛋白
依摺麥佈%瑞舒伐他汀%冠心病臨界病變%超敏C-反應蛋白
의절맥포%서서벌타정%관심병림계병변%초민C-반응단백
Ezetimibe%Rosuvastatin%Coronary boderline lesions%High sensitivity C-reactive protein
目的 观察依折麦布和瑞舒伐他汀联合应用,强效降脂治疗对冠状动脉临界病变患者冠状动脉斑块以及炎症因子的影响,并分析可能的相关机制.方法 选取冠状动脉临界病变合并高脂血症患者47例,随机分为两组,依折麦布+瑞舒伐他汀组22例,给予依折麦布10 mg,每日睡前服用+瑞舒伐他汀10 mg,每日睡前服用；瑞舒伐他汀组25例,给予瑞舒伐他汀10 mg,每日睡前服用.分别于治疗前及治疗后6个月检测血脂水平和高敏C-反应蛋白(hs-CRP)水平,以血管内超声(IVUS)和虚拟组织成像技术(VH-IVUS)检测治疗前后冠状动脉内斑块面积和成分变化.结果 治疗6个月后,依折麦布+瑞舒伐他汀组能进一步降低血总胆固醇、低密度脂蛋白胆固醇及hs-CRP水平,与瑞舒伐他汀组比较差异有统计学意义.同时依折麦布+瑞舒伐他汀组较瑞舒伐他汀组能显著降低斑块负荷、斑块截面积、薄纤维帽斑块的比率以及斑块中坏死成分百分比(P＜0.05).结论 依折麦布+瑞舒伐他汀组可明显降低血脂水平和斑块负荷,改善斑块的稳定性,这可能与其能强效抑制炎症因子表达有关.
目的 觀察依摺麥佈和瑞舒伐他汀聯閤應用,彊效降脂治療對冠狀動脈臨界病變患者冠狀動脈斑塊以及炎癥因子的影響,併分析可能的相關機製.方法 選取冠狀動脈臨界病變閤併高脂血癥患者47例,隨機分為兩組,依摺麥佈+瑞舒伐他汀組22例,給予依摺麥佈10 mg,每日睡前服用+瑞舒伐他汀10 mg,每日睡前服用；瑞舒伐他汀組25例,給予瑞舒伐他汀10 mg,每日睡前服用.分彆于治療前及治療後6箇月檢測血脂水平和高敏C-反應蛋白(hs-CRP)水平,以血管內超聲(IVUS)和虛擬組織成像技術(VH-IVUS)檢測治療前後冠狀動脈內斑塊麵積和成分變化.結果 治療6箇月後,依摺麥佈+瑞舒伐他汀組能進一步降低血總膽固醇、低密度脂蛋白膽固醇及hs-CRP水平,與瑞舒伐他汀組比較差異有統計學意義.同時依摺麥佈+瑞舒伐他汀組較瑞舒伐他汀組能顯著降低斑塊負荷、斑塊截麵積、薄纖維帽斑塊的比率以及斑塊中壞死成分百分比(P＜0.05).結論 依摺麥佈+瑞舒伐他汀組可明顯降低血脂水平和斑塊負荷,改善斑塊的穩定性,這可能與其能彊效抑製炎癥因子錶達有關.
목적 관찰의절맥포화서서벌타정연합응용,강효강지치료대관상동맥림계병변환자관상동맥반괴이급염증인자적영향,병분석가능적상관궤제.방법 선취관상동맥림계병변합병고지혈증환자47례,수궤분위량조,의절맥포+서서벌타정조22례,급여의절맥포10 mg,매일수전복용+서서벌타정10 mg,매일수전복용；서서벌타정조25례,급여서서벌타정10 mg,매일수전복용.분별우치료전급치료후6개월검측혈지수평화고민C-반응단백(hs-CRP)수평,이혈관내초성(IVUS)화허의조직성상기술(VH-IVUS)검측치료전후관상동맥내반괴면적화성분변화.결과 치료6개월후,의절맥포+서서벌타정조능진일보강저혈총담고순、저밀도지단백담고순급hs-CRP수평,여서서벌타정조비교차이유통계학의의.동시의절맥포+서서벌타정조교서서벌타정조능현저강저반괴부하、반괴절면적、박섬유모반괴적비솔이급반괴중배사성분백분비(P＜0.05).결론 의절맥포+서서벌타정조가명현강저혈지수평화반괴부하,개선반괴적은정성,저가능여기능강효억제염증인자표체유관.
Objective To observe the effect of ezetimibe combined with rosuvastatin on coronary plaques and high sensitivity C-reactive protein(hs-CRP) level in patients with coronary boderline lesions,and analyze the possible machanism.Methods A total of 47 patients with coronary boderline lesions were randomly divided into two groups,22 patients in ezetimibe combined with rosuvastatin treatment group were given ezetimibe 10 mg,quaque nocte and rosuvastatin 10 mg,quaque nocte; Twenty-five patients in rosuvastatin treatment group were given rosuvastatin 10 mg,quaque nocte.Serum lipid and hs-CRP levels were detected before treatment and 6 months after treatment.Coronary plaques area and plaques composition were detected by intravascular unltrasound and VH-IVUS at the same time.Results At 6 months after treatment,compared with rosuvastatint treatment group,ezetimibe and rosuvastatin combined treatment could significantly reduce the serum lipid and hs-CRP levels,there were significant differences.At the same time,ezetimibe and rosuvastatin combined treatment significantly decreased coronary plaques area,plaques burden,thin fibrous cap plaques ratio and percentage of necrosis element in plaques.Conclusions Ezetimibe and rosuvastatin combined treatment can significantly decrease serum lipid level,coronary plaques area and plaques burden of coronary boderline lesions,which may be associated with reduced hs-CRP level.
